Candida krusei is well known as a fungal pathogen for patients with hematologic malignancies and for transplant recipients. Using the ARTEMIS Antifungal Surveillance Program database, we describe geographic and temporal trends in the isolation of C. krusei from clinical specimens and the in vitro susceptibilities of 3,448 isolates to voriconazole as determined by CLSI (formerly NCCLS) disk diffusion testing. In addition, we report the in vitro susceptibilities of bloodstream infection isolates of C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates), caspofungin (300 isolates), and micafungin (102 isolates) as determined by CLSI broth microdilution methods. Geographic differences in isolation were apparent; the highest frequency of isolation was seen for the Czech Republic (7.6%) and the lowest for Indonesia, South Korea, and Thailand (0 to 0.3%). Overall, 83% of isolates were susceptible to voriconazole, ranging from 74.8% in Latin America to 92.3% in North America. C. krusei was most commonly isolated from hematology-oncology services, where only 76.7% of isolates were susceptible to voriconazole. There was no evidence of increasing resistance of C. krusei to voriconazole from 2001 to 2005. Decreased susceptibilities to amphotericin B (MIC at which 90% of isolates were inhibited [MIC 90 ], 4 g/ml) and flucytosine (MIC 90 , 16 g/ml) were noted, whereas 100% of isolates were inhibited by <2 g/ml of anidulafungin (MIC 90 , 0.06 g/ml), micafungin (MIC 90 , 0.12 g/ml) or caspofungin (MIC 90 , 0.25 g/ml). C. krusei is an uncommon but multidrugresistant fungal pathogen. Among the systemically active antifungal agents, the echinocandins appear to be the most active against this important pathogen.
Candida krusei has been recognized as a potentially multidrug-resistant (MDR) fungal pathogen, due to its intrinsic fluconazole resistance combined with reports of decreased susceptibility to both flucytosine and amphotericin B (1, 2, 3, 6, 20, 22, 23, 26, 37, 39, 47, 61) . Several authors have reported breakthrough infections due to C. krusei among patients receiving fluconazole or amphotericin B (1, 11, 19, 21, 31, 34, 61) , and Goldman et al. (9) found that response rates of C. krusei infection were significantly better for patients who had received amphotericin B in doses of Ն1 mg/kg of body weight per day than for those who had received lower doses. Furthermore, amphotericin B exhibits markedly delayed killing kinetics against C. krusei compared with that against Candida albicans (4, 19) .
The MDR phenotype exhibited by C. krusei poses a therapeutic dilemma when one is considering treatment choices for neutropenic and critically ill patients, especially for those with prior exposure to fluconazole (32, 54, 56, 57) . Despite intrinsic resistance to fluconazole, C. krusei usually remains susceptible in vitro to voriconazole due to the more effective binding of voriconazole to the cytochrome P-450 isoenzyme of C. krusei (7, 48) . Furthermore, voriconazole has been used successfully to treat some patients infected with C. krusei (16, 29) . In addition, the echinocandins have been used based on their fungicidal activity and excellent in vitro activity against C. krusei (41, 42, 56, 57) . Whereas echinocandin antifungals such as caspofungin have been used successfully to treat several different infections involving C. krusei (21, 28, 31, 34, 50) , there have been recent troubling reports of caspofungin failure in the treatment of C. krusei infections (10, 15, 33) . Notably, Hakki et al. (10) reported a strain of C. krusei from a leukemic patient that displayed reduced susceptibilities to caspofungin, anidulafungin, and micafungin. The strain emerged during therapy with caspofungin and subsequently was shown to contain a heterozygous mutation in the FKS1 gene resulting in altered sensitivity of the glucan synthesis enzyme complex to inhibition by echinocandin drugs (15) . These findings emphasize the plasticity of C. krusei with respect to the development of resistance to a broad array of antifungals. Along with Candida glabrata, C. krusei must be considered an important indicator species that should be monitored for the development of antifungal resistance (15, 47) .
Despite the MDR phenotype exhibited by C. krusei, few studies have addressed the global epidemiology and antifungal susceptibility profile of C. krusei (23) . Most of the available information regarding C. krusei comes from single institutions (1) or represents a limited geographic region (23 Data for C. krusei were stratified by year of isolation, geographic region, clinical service (hospital location), and specimen type. Candida spp. considered by the local site investigator to be colonizers, that is, not associated with pathology, were excluded, as were duplicate isolates (the same species and the same susceptible-resistant biotype profile within any 7-day period). Isolates were identified in accordance with each site's routine methods (49) .
Susceptibility test methods. Disk diffusion testing of voriconazole was performed as described previously (49) and in accordance with CLSI document M44-A (25) . Agar plates (diameter, 90, 100, or 150 mm) containing MuellerHinton agar (obtained locally at all sites) supplemented with 2% glucose and 0.5 g of methylene blue per ml at a depth of 4.0 mm were used. The agar surface was inoculated by using a swab dipped in a cell suspension adjusted to the turbidity of a 0.5 McFarland standard. Voriconazole (1 g) disks (Becton Dickinson, Sparks, MD) were placed on the surfaces of the inoculated plates, and the plates were incubated in air at 35 to 37°C and read at 18 to 24 h. Zone diameter end points were read at 80% growth inhibition by using a BIOMIC image analysis plate reader system (Giles Scientific, Santa Barbara, CA) (49) .
MICs of flucytosine, anidulafungin, caspofungin, and micafungin were determined by broth microdilution as described previously (36, (41) (42) (43) . All isolates were tested in RPMI broth with a 24-h (anidulafungin, caspofungin, and micafungin) or 48-h (flucytosine) incubation and an end point criterion of a prominent reduction in growth relative to that of the control (represented by Ն50% growth inhibition). The susceptibilities of C. krusei isolates to amphotericin B were determined by using Etest (AB Biodisk) as described previously (38) .
The interpretive criteria for the voriconazole disk diffusion tests were those of the CLSI (44), as follows: susceptible (S), zone diameter of Ն17 mm; susceptible dose dependent (SDD), zone diameters of 14 to 16 mm; resistant (R), zone diameters of Յ13 mm. The corresponding MIC breakpoints (44) are as follows: S, MIC of Յ1 g/ml; SDD, MIC of 2 g/ml; R, MIC of Ն4 g/ml.
The interpretive criteria for all three echinocandins were those recently assigned by the CLSI (minutes of June 2007 CLSI meeting). Isolates for which the MIC is Յ2 g/ml are designated S. A category of R has not been established for the echinocandins due to a paucity of "resistant" isolates treated with an echinocandin. Those isolates for which an echinocandin MIC is Ͼ2 g/ml are to be designated "nonsusceptible."
The interpretive criteria for flucytosine were those recommended by the CLSI (24): S, MIC of Յ4 g/ml; intermediate (I), MIC of 8 to 16 g/ml; R, MIC of Ն32 g/ml. Interpretive breakpoints have not been established for amphotericin B.
QC. Quality control (QC) was performed in accordance with CLSI documents M44-A (voriconazole) and M27-A2 (all other agents) by using Candida albicans ATCC 90029, Candida parapsilosis ATCC 22019, and C. krusei ATCC 6258 (24, 25) . More than 99% of QC results were within the acceptable limits.
Analysis of results. All disk zone diameters were read by electronic image analysis and interpreted and recorded with the BIOMIC plate reader system (Giles). Test results were sent by e-mail to Giles Scientific for analysis. The zone diameter, susceptibility category (S, SDD, or R), and QC test results were all recorded electronically. Patient and doctor names, duplicate test results (same patient, same species, and same biotype results), and uncontrolled results were automatically eliminated by the BIOMIC system prior to analysis. In the present study, voriconazole S, SDD, and R results for C. krusei were stratified by year of collection, geographic region, clinical specimen type, and hospital location. The chi-square test, with Yates' correction, was used to determine the statistical significance of differences in voriconazole isolation or susceptibility according to other categorical variables. Alpha was set at 0.05, and all reported P values are two-tailed.
RESULTS
Isolation rates of C. krusei over time and by geographic region. A total of 137,487 isolates of Candida spp. were recovered and identified at 124 study sites between January 2001 and December 2005 (49) . C. krusei ranked fifth among 22 different species of Candida, accounting for 2.5% of all isolates ( Table 1 ). The frequency of isolation of C. krusei did not change (range, 2.3 to 2.7%) over the course of the study.
C. krusei represented 3.3% of all Candida spp. isolated in both Europe and North America (3.5% in the United States, 1.8% in Canada) ( Table 1 ). In Europe, C. krusei was isolated most frequently (Ն5% of all Candida sp. isolates) in the Eastern European countries of the Czech Republic (7.6%), Poland (6.0%), and Slovakia (5.1%) and was distinctly uncommon (Ͻ1%) in The Netherlands (0.5%). C. krusei was also quite uncommon in the Asia-Pacific region (1.3%) and Latin America (1.7%). Fewer than 1% of all Candida strains isolated in Indonesia (0%), South Korea (0.3%), Taiwan (0.6%), Thailand (0.3%), and Ecuador (0.5%) were identified as C. krusei (Table 1) .
Geographic differences in the susceptibility of C. krusei to voriconazole. Table 1 presents the in vitro susceptibility of C. krusei to voriconazole stratified by country and geographic region of origin, as determined by CLSI disk diffusion testing. Overall, C. krusei exhibited decreased susceptibility to voriconazole (82.9% S, 7.8% R) compared to that of C. albicans (98.4% S, 1.2% R) (data not shown).
Considerable differences in the susceptibility of C. krusei to voriconazole were observed across the five broad regions: isolates from North America were the most susceptible (92.3% S, 4.3% R), while the lowest overall susceptibility was seen among isolates from Latin America (74.8% S, 16.0% R; P Ͻ 0.001 for the difference between North America and Latin America in the proportion of C. krusei isolates that were susceptible to voriconazole). The lowest susceptibilities to voriconazole (Ͻ70%) were seen in the Latin American countries of Brazil (65.9% S, 34.1% R), Colombia (61.8% S, 18.2% R), and Mexico (63.6% S, 36.4% R). No other country reported susceptibility rates of less than 70%. In contrast, susceptibility rates exceeded 90% in 14 countries: Australia (100%), Taiwan (94.7%), Thailand (100%), Belgium (97.3%), Germany (90.9%), The Netherlands (100%), Poland (98.4%), Portugal (96.1%), Slovakia (90.1%), Switzerland (93.6%), Argentina (93.8%), Israel (94.7%), Canada (93.8%), and the United States (92.2%). These extreme differences in the susceptibility of C. krusei to voriconazole are important to understand and monitor, and they emphasize the importance of antifungal susceptibility testing of this species if voriconazole is considered a therapeutic option.
Trends in resistance to voriconazole among C. krusei isolates over time. Differences in the frequency of isolation and the voriconazole susceptibility profile of C. krusei by clinical service. The clinical services reporting the isolation of C. krusei from patient specimens included the hematology-oncology service, medical and surgical services, intensive care units (medical, surgical, and neonatal), the dermatology service, the obstetrics and gynecology (ObGyn) service, the urology service, and the outpatient service (Table 2) . Those strains from services with only a few isolates and those for which a clinical service was not specified were included in the category "other, not otherwise specified" (other, NOS).
As expected, C. krusei represented a higher proportion of Candida strains isolated from patients hospitalized in hematology-oncology services than from all other services combined (6.2% versus 2.3%; P Ͻ 0.001). C. krusei was especially uncommon among Candida isolates from the dermatology, ObGyn, and outpatient services. Voriconazole was least active against isolates from the dermatology (68.0%) and urology (73.1%) services and most active against isolates from the medical (82.7%) and surgical (82.6%) services and from the unspecified (other, NOS) group (88.5%). Fewer than 80% of isolates from the hematology-oncology service were susceptible to voriconazole (76.7%).
Differences in the frequency of isolation and the voriconazole susceptibility profile of C. krusei by clinical specimen type. The major specimen types yielding C. krusei as a putative pathogen included blood, NSBF, urine, respiratory, general, and skin/soft tissue specimens (Table 3) . Those isolates from uncommon specimen types and those for which a specimen type was not recorded were grouped under the category "miscellaneous, NOS."
C. krusei was isolated from 2 to 3% (each) of blood, NSBF, urine, respiratory, and skin/soft tissue specimens. It was isolated infrequently from genital specimens. Interestingly, C. krusei isolates from blood were more likely to be susceptible to voriconazole than those from urine (89.0 versus 76.6%, respectively; P Ͻ 0.001). This pattern was similar to that reported previously for another uncommon species of Candida, Candida guilliermondii (45). Activities of amphotericin B, flucytosine, and the echinocandins against bloodstream isolates of C. krusei. Among the 326 BSI isolates of C. krusei collected during this survey, 304 isolates were sent to the University of Iowa for further testing against amphotericin B (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates), caspofungin (300 isolates), and micafungin (102 isolates) ( Table 4 ). Our broth dilution antifungal susceptibility testing panels changed during the 5-year span of the study, which explains why the numbers of isolates tested against each of the agents differ somewhat (e.g., anidulafungin and micafungin were added to the panel, and flucytosine was dropped, in the latter years of the study).
Among the BSI isolates tested, decreased susceptibilities to amphotericin B (MIC at which 90% of isolates were inhibited [MIC 90 ], 4 g/ml) and flucytosine (MIC 90 , 16 g/ml; 8% S) were noted. By comparison, the MIC 90 s of amphotericin B and flucytosine tested against C. albicans were 0.5 g/ml and 1.0 g/ml, respectively (data not shown). All isolates of C. krusei were susceptible to the three echinocandins at the CLSI breakpoint concentration of Յ2 g/ml: MIC 90 s were 0.06 g/ml for anidulafungin, 0.12 g/ml for micafungin, and 0.25 g/ml for caspofungin.
DISCUSSION
The results from this extensive survey of C. krusei both confirm and extend previous observations concerning this species (1, 3, 6, 22, 23, 39, 40, 47, 52 ). C. krusei remains a relatively uncommon clinical isolate throughout the world (Table 1) . Most notable is the very low frequency of isolation in both the Asia-Pacific and Latin American regions as opposed to the higher frequency observed in several Eastern European countries. This could represent geographic differences in the ecology of Candida species or in the use of cytotoxic drugs and antimicrobial agents (22) . C. krusei is most common among patients with hematologic malignancies and recipients of blood and marrow transplants (1, 2, 12, 20, 26, 61 ). Whether this observation is a direct result of fluconazole administration remains controversial, since others have reported infections due to this species before the introduction of fluconazole (14, 22, 60) . In addition, several centers have reported no increased incidence of infections with C. krusei, despite the widespread use of fluconazole (8, 17, 18, 51, 55) . As reported in several smaller studies (5, 6, 10, 23, 30, 34, 37, 39, 55) , C. krusei was generally susceptible to voriconazole, although considerable geographic differences were seen (Table 1) , like those seen with C. glabrata (49) and Candida rugosa (46) .
There was less variability in voriconazole susceptibility across the different clinical services (Table 2 ) and specimen types (Table 3) . Notably, BSI isolates of C. krusei exhibited the greatest susceptibility to voriconazole. Although isolates of C. krusei from blood and NSBF are clearly pathogenic, the isolation of this organism from nonsterile sites (e.g., urine, respiratory, and genital specimens) may simply represent colonization rather than infection. That said, colonization with C. krusei precedes infection in approximately 70% of patients (1, 9, 13, 26, 35, 53, 59) , and colonizing strains of C. krusei have been shown to be indistinguishable from BSI isolates obtained from the same patient, supporting the role of this species as an endogenous pathogen (3, 27, 58) . Thus, the isolation of C. krusei from nonsterile sites may have direct bearing on the selection of antifungal therapy.
We document a pattern of decreased susceptibility of C. krusei to amphotericin B and flucytosine that, along with intrinsic resistance to fluconazole, results in an MDR phenotype. As seen previously (41, 43) , the echinocandins were all active against BSI isolates of C. krusei. The activity of this class of antifungal agents against this MDR pathogen is encouraging; however, the reports of resistance developing to caspofungin during the treatment of C. krusei infection must be kept in mind. The reduced susceptibility to caspofungin in both cases was associated with the onset of clinically apparent fungal infection involving anatomic sites, such as the eye (10) or the central nervous system (33) , where adequate free drug levels cannot be readily obtained. In such instances, the availability of an agent such as voriconazole, with both activity against the infecting organism and good penetration into ocular and cen- Amphotericin B  304  4  4  5  7  24  51  85  98  99  100  Flucytosine  254  1  1  1  1  2  5  8  26  93  99  99  Anidulafungin  121  49  92  99  99  100  Caspofungin  300  1  40  69  90  98  99  100  Micafungin  102  12  84  99  100 a Amphotericin B MICs were determined by Etest after 24 h of incubation. Echinocandin MICs were determined using RPMI 1640 broth with 24 h of incubation and an end point criterion of a prominent reduction in growth (MIC-2).
tral nervous system sites, may be vital to a successful outcome (33) . Continued monitoring of the susceptibility of C. krusei to voriconazole and the echinocandins is clearly warranted.
In summary, we have used data from the ARTEMIS DISK Antifungal Surveillance Program (49) to increase our understanding of C. krusei as an opportunistic fungal pathogen. Our findings demonstrate considerable geographic diversity both in its occurrence and in its susceptibility to the expanded-spectrum triazole voriconazole. In addition to resistance to fluconazole, this species clearly exhibits decreased susceptibility to amphotericin B and flucytosine. Given the variable activity of voriconazole against this species, demonstrated here, and recent reports of acquired resistance to echinocandins, testing of the susceptibility of C. krusei to these potentially useful antifungal agents may be warranted to help guide therapeutic decisions.
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